Tell us about you

Work Email required

Organization required

First Name required

Last Name required

Job Title required

Phone required (###) ###-####, or int ######...

City required

State/Province required

Business Information

Tell us about your organization

error messages will go here...

Looks like we’re already familiar with you!

Please press next to continue with the survey.

Looks like we’re already familiar with you!

According to your account type you are not eligible to take surveys at this time. If this is a mistake, please contact KLAS.

If you are trying to access KLAS research data and reports, an email has been sent to   with a link to login.

If the email doesn't appear in your inbox, ask your IT department to add KLASresearch.com to your company spam filter's "whitelist", and check your email's spam folder.

Membership Commitment

In exchange for giving their feedback, healthcare providers can create an account to get access to industry reports, user commentary, and real-time ratings.

By submitting your account request, you are engaged in patient care as either an employee (or contractor) of your provider organization and that you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.

To learn more about how we process and protect your personal data, you may view our Privacy policy.

By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically. To learn more about how we process and protect your personal data, you may view our Privacy policy.

By submitting your account request, you confirm that you have reviewed and agree to abide by the Terms of Use for this website as updated periodically.

To learn more about how we process and protect your personal data, you may view our Privacy policy.

 

To learn more about how we process and protect your personal data, you may view our Privacy policy.

 

To learn more about how we process and protect your personal data, you may view our Privacy policy.

Thank You! Your information was submitted successfully!

Next Steps - An email has been sent to . Please follow its instructions to verify your email, and login.

If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.

Thank You! Your information was submitted successfully!

Next Steps - A KLAS representative will contact you to discuss working with KLAS, typically within 24 to 48 hours.

If you have any further questions please contact info@klasresearch.com or 1-800-920-4109.

Surprise! Looks like we already have an account for you.

An email has been sent to blah@blah.com with a link to login.

If the email doesn't appear in your inbox, try asking your IT department to add KLASresearch.com to your company spam filter's "whitelist", and checking your email's spam folder.

Thank you !

Access info about on your dashboard or bookmark under

(Your Products / Your Organization's Products)

Medial EarlySign

Headquarters:

Kfar Malal Tel Aviv, Israel

Sector Funding:

Go to Website

Medial EarlySign's Current COVID-19 Response and Solutions

The following information was supplied by the vendor and has not been validated by KLAS.

AlgoAnalyzer

Identifies patients estimated to be at increased risk of suffering severe complications if infected with coronavirus

EarlySign Invites you to Discover our COVID-19 Complications Risk Predictor

We have seen how COVID-19 negatively impacts the community and creates a massive burden to the health system. With emotional distress, significant economic anxiety, and physical suffering for individuals, early action is critical.

Working together with health system partners around the world, EarlySign’s new AI-based clinical risk predictor has been shown to identify patients estimated to be at increased risk of suffering severe complications if infected with coronavirus. With the goal of prioritizing patients for COVID-19 testing and treatment, the new AlgoMarker aids in speeding the determination whether patients are at high risk for hospitalization, complications, and mortality.

The result: More patients at high risk see their medical conditions addressed earlier and essential clinical resources are used more efficiently and effectively.

“Immediate action is critical to combat this pandemic, and we are taking urgent steps to massively impact human health,” stated EarlySign CEO Jeremy Orr, MD, MPH. “Our goal is to provide health systems a fast, reliable approach to identify and connect with patients at highest risk. We believe it to our shared mission to make this available at no cost or obligation.”



Thank you !

Access info about on your dashboard or bookmark under

(Your Products / Your Organization's Products)

Software Overall Score Data collected between Feb 2020 - Feb 2021


 Product
Segment
 

Exceptions

R
Regional Classification
C
Component Products
S
Superseded Products
NP
Not Primary Products
DR
Data Review
MS
Limited Market Share
FR
Data frozen, live data no longer collected.

The following exceptions refer to the number of unique organizations contributing evaluations to the overall score (minimum of 15 required).

# of Unique Organization Evaluations:

0 - 5
L 6 - 14

Segment Position

Segment positions refer to the order in which this product is scored among competitors’ products within its market segment.

In order to be scored in a segment, the product must have sufficient data levels and be equivalent in scope to other products within that segment.

Click the segment positions listed below to learn more.